Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis of confounder-adjusted 20212 hospitalized patients

Min Seo Kim, Min Ho An, Won Jun Kim, Tae-Ho Hwang
doi: https://doi.org/10.1101/2020.06.15.20132407
Min Seo Kim
1Korea University, College of Medicine, Seoul, Republic of Korea
4Cheongsan Public Health Center, Wando, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: minseolike@naver.com
Min Ho An
2Ajou University, School of Medicine, Suwon, Republic of Korea
5So Ahn Public Health Center, Wando, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Won Jun Kim
1Korea University, College of Medicine, Seoul, Republic of Korea
7Gangneung Prison Medical Department, Ministry of Justice, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tae-Ho Hwang
3Department of pharmacology, Pusan National University, School of Medicine, Yangsan, Republic of Korea
6Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine, Pusan National University, Yangsan, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: minseolike@naver.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective To evaluate the comparative efficacy and safety of pharmacological interventions used in treating COVID-19 and form a basis for an evidence-based guideline of COVID-19 management by evaluating the level of evidence behind each treatment regimen in different clinical settings.

Design Systematic review and network meta-analysis

Data Sources PubMed, Google Scholar, MEDLINE, the Cochrane Library, medRxiv, SSRN, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov up to June 9th, 2020.

Study Selection Published and unpublished randomized controlled trials (RCTs) and baseline-adjusted observational studies which met our predefined eligibility criteria.

Main Outcome Measures The outcomes of interest were mortality, progression to severe disease (severe pneumonia or admission to intensive care unit (ICU)), time to viral clearance, QT prolongation, fatal cardiac complications, and non-cardiac serious adverse events. The level of evidence behind each outcome was also measured using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.

Results 49 studies with a total of 20212 confounder-adjusted patients were included for analysis. The risk of progression to severe pneumonia or ICU admission was significantly reduced with tocilizumab (GRADE low), anakinra (GRADE very low), and remdesivir (GRADE high) compared to standard care. Tocilizumab was shown to reduce mortality rate for both moderate-severe patients in the non-ICU setting at admission (Odds ratio (OR) 0.31, 95% confidence interval (CI) 0.18 to 0.54, GRADE low) and critically ill patients in the ICU setting (OR 0.67, 95% CI 0.50 to 0.91, GRADE low). High dose IVIG reduced death rate (GRADE low) while corticosteroids increased mortality for critically ill patients (GRADE moderate). Convalescent plasma and hydroxychloroquine were shown to promote viral clearance (OR 11.39, 95% CI 3.91 to 33.18, GRADE low and OR 6.08, 95% CI 2.74 to 13.48, GRADE moderate, respectively) while not altering mortality or progression to the severe courses. The combination of hydroxychloroquine and azithromycin was shown to be associated with increased QT prolongation incidence (OR 1,85, 95% CI 1.05 to 3.26, GRADE low) and fatal cardiac complications in cardiac-impaired populations (OR 2.26, 95% CI 1.26 to 4.05, GRADE low). High-dose (>600mg/day) hydroxychloroquine monotherapy was significantly associated with increased non-cardiac serious adverse events (GRADE moderate).

Conclusion Anti-inflammatory agents (tocilizumab, anakinra, and IVIG) and remdesivir may safely and effectively improve outcomes of hospitalized COVID-19 patients. Widely used hydroxychloroquine provides marginal clinical benefit in improving viral clearance rates whilst posing both cardiac and non-cardiac safety risks, especially in the vulnerable population. Only 20% of current evidence on pharmacological management of COVID-19 is on moderate and high evidence certainty and can be considered in practice and policy; remaining 80% are of low or very low certainty and warrant further studies to establish firm conclusions.

Systematic Review Registration PROSPERO 2020: CRD42020186527.

Section 1: What is already known on this topic

  • - Numerous clinical trials and observational studies have investigated various pharmacological agents as potential treatment for COVID-19.

  • - Results from numerous studies are heterogeneous and sometimes even contradictory to one another, making it difficult for clinicians to determine which treatments are truly effective.

  • - Level of evidence behind each outcome from diverse studies remains unknown.

Section 2: What this study adds

  • - Anti-inflammatory agents (tocilizumab, anakinra, and IVIG) and remdesivir may safely and effectively improve clinical outcomes of COVID-19.

  • - Widely used hydroxychloroquine provides marginal clinical benefit in improving viral clearance rates whilst posing both cardiac and non-cardiac safety risks.

  • - Only 20% of current evidence on pharmacological management of COVID-19 is on moderate/high evidence certainty and can be considered in practice and policy; remaining 80% are of low or very low certainty and warrant further studies to establish firm conclusions.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

There was no funding source for this study. MS Kim and MH An had full access to all of the data in the study and MS Kim and T Hwang had final decision responsibility to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable. This study involves a systematic review and thus all data are available in open sources.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • This manuscript has been reviewed and is approved by all authors.

  • Min Seo Kim, Min Ho An, Won Jun Kim, Tae-Ho Hwang have no commercial associations that may present a conflict of interest in relation to this manuscript.

Data Availability

Not applicable. This study is a systematic review and thus involve data available in open sources and publications.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 19, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis of confounder-adjusted 20212 hospitalized patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis of confounder-adjusted 20212 hospitalized patients
Min Seo Kim, Min Ho An, Won Jun Kim, Tae-Ho Hwang
medRxiv 2020.06.15.20132407; doi: https://doi.org/10.1101/2020.06.15.20132407
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis of confounder-adjusted 20212 hospitalized patients
Min Seo Kim, Min Ho An, Won Jun Kim, Tae-Ho Hwang
medRxiv 2020.06.15.20132407; doi: https://doi.org/10.1101/2020.06.15.20132407

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (196)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5677)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (863)
  • Geriatric Medicine (88)
  • Health Economics (230)
  • Health Informatics (761)
  • Health Policy (390)
  • Health Systems and Quality Improvement (251)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6471)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (91)
  • Neurology (847)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (162)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (965)
  • Public and Global Health (2226)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)